Tag Archive for: American Society of Hematology

Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting

/in

All doses of POLB 001 significantly reduced clinically observed Cytokine Release Syndrome scores POLB 001 treatment showed statistically significant reductions in key cytokines  Positive results reinforce the use case for POLB 001 in the prevention and treatment of cancer immunotherapy-induced CRS 9 December 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused […]

Read more

Poolbeg Pharma plc to present POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting

/in

POLB 001 Reduces Cytokine Release Syndrome (CRS) in an in vivo animal model Positive results reinforce POLB 001’s potential in the prevention and treatment of cancer immunotherapy-induced CRS ASH is the world’s premier conference focussing on haematological malignancies 6 November 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development […]

Read more